Padma P. Tadi Uppala Discussed Research Analyzing Natural Therapies to Combat COVID-19


A presentation from the AACR Virtual Meeting: COVID-19 and Cancer detailed a literature review of natural therapeutics and remedies to combat the SARS CoV-2 virus.

CancerNetwork® spoke with Padma P. Tadi Uppala, professor and director of the Public Health Program at Andrews University, regarding her research from the AACR Virtual Meeting: COVID-19 and Cancer.

Uppala, along with her research partners, performed an exploratory analysis about evidence-based natural therapies and foods that naturally enhance the immune system with the goal of combatting the SARS CoV-2 virus.

“It’s a systematic literature review of evidence-based natural therapies to prevent and treat COVID-19,” explained Uppala. “It’s based on the fact that SARS CoV-2 dysregulates the innate immune system, so I wanted to look at literature to find if natural therapies can strengthen the innate immune system.”

The results, which relied heavily on data about the 1918 Spanish Flu as well as existing literature, found that foods such as blueberries, garlic, and probiotics were shown to improve natural killer activity, while Vitamin C, Vitamin D, Zinc, and selenium were integral in immunity.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

Related Videos
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.
Lucio N. Gordan, MD, also discusses how increasing domestic manufacturing of chemotherapy may help in alleviating the ongoing shortages of carboplatin and cisplatin in the United States.
Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, believes that national legislation can help to resolve the United States’ current dearth of cisplatin, as well as prevent future problems.
Using an AUC of 5 instead of an AUC of 6 can help to conserve cisplatin among patients with cancer, Kirollos Hanna, PharmD, BCPS, BCOP, FACCC says.
While there is a cisplatin shortage in the United States, the FDA has approved the importation of select chemotherapy drugs from China to help mitigate the scarcity of the agents.
Recommendations penned by the American Society of Clinical Oncology and Society for Gynecologic Oncology may be critical in managing the ongoing chemotherapy shortage, according to Michael Ganio, PharmD, MS, BCPS, FASHP.
Chemotherapy agents imported from Chinese manufacturers may have barcodes that don’t work or be missing an NDC number, according to Michael Ganio, PharmD, MS, BCPS, FASHP.
Results of a survey from the National Comprehensive Cancer Network indicate that almost all responding institutions are experiencing a carboplatin shortage.
Although opioid use guidelines from the Centers for Disease Control exclude patients with cancer, drug screenings are required that could further contribute to racial disparities.
Related Content